Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations

Next Previous
X
Search
Trial Profile

A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vevorisertib (Primary) ; Fulvestrant; Paclitaxel
  • Indications Advanced breast cancer; Colon cancer; Endometrial cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors ArQule; Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 27 Mar 2023 Results published in the Cancer
    • 14 Jun 2022 The primary endpoint Incidence of adverse events graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) guidelines v4.03 was changed to Number of Participants Who Experience One or More Adverse Events (AEs) and Number of Participants Who Discontinue Study Treatment Due to an AE, according to ClinicalTrials.gov record.
    • 16 Apr 2021 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top